Long non-coding RNA small nucleolar RNA host gene 7 is upregulated and promotes cell proliferation in thyroid cancer

LI CHEN1*, JING ZHU2* and LING-JIE ZHANG3

Departments of 1Endocrinology and 2Clinical Laboratory, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei 434020; 3Department of Anesthesiology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei 430015, P.R. China

Received September 12, 2019; Accepted June 6, 2019

DOI: 10.3892/ol.2019.10782

Abstract. Thyroid cancer (THCA) is one of the most common types of endocrine cancer worldwide. However, the mechanisms underlying THCA progression have not been fully elucidated. Recent studies have demonstrated that long non-coding RNAs (lncRNAs) are dysregulated in human diseases, and are involved in regulating various biological processes. Furthermore, several reports have indicated that lncRNAs serve important roles in THCA. In the present study, a dataset from The Cancer Genome Atlas was used to analyze the expression levels and the clinical information of small nucleolar RNA host gene 7 (SNHG7) in THCA. Starbase was used to construct the competing endogenous RNA network. The Molecule Annotation System was used to analyze the data from Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. Furthermore, cell proliferation and cell cycle assays were used to detect the functions of SNHG7 in THCA. The present study revealed for the first time, to the best of our knowledge, that SNHG7 is markedly upregulated in THCA samples following analysis of The Cancer Genome Atlas datasets. SNHG7 expression was higher in advanced stage compared with early stage THCA samples. In addition, high expression levels of SNHG7 were associated with shorter survival times in THCA patients compared with low expression levels. Bioinformatics analysis revealed that SNHG7 was associated with the processes of ‘protein translation’, ‘viral life cycle’, ‘RNA processing’, ‘mRNA splicing’, ‘histone ubiquitination’, ‘endoplasmic reticulum-to-Golgi vesicle-mediated transport’, ‘sister chromatid cohesion’, ‘DNA damage checkpoint regulation’, ‘translation’ and ‘the spliceosome’. Additionally, knockdown of SNHG7 significantly inhibited thyroid cancer cell proliferation and cell cycle progression in vitro. Taken together, the results obtained in the present study suggested that SNHG7 may serve as a novel therapeutic and prognostic target for THCA.

Introduction

Thyroid cancer (THCA) is one of the most common types of endocrine cancer worldwide (1,2). Accumulating evidence has indicated that numerous biomarkers are involved in THCA prognosis, proliferation and radiation resistance. For example, Huang et al (3) observed that downregulation of microRNA (miR)-125a-5p promoted glucose metabolism by upregulating CD147 in THCA. Furthermore, Choi et al (4) demonstrated that prospero homeobox 1 activates Wnt/β-catenin signaling, and induces the expression of serpin family A member 1 and fatty acid binding protein 4 in papillary THCA. However, the mechanisms underlying THCA progression have not been fully elucidated.

Long noncoding RNAs (lncRNAs) are a type of RNA transcript that are >200 bp in length, but which have no protein coding potential (5). Previous studies have revealed that lncRNAs are dysregulated in a number of human diseases, and are involved in regulating various biological processes, including RNA stabilization (6,7), X chromosome inactivation (8,9), transcription and protein translation (10). Several reports have demonstrated that lncRNAs serve important roles in THCA. For example, a recent study demonstrated that nuclear-enriched abundant transcript 1_2 is able to ‘sponge’ (or competitively inhibit) miR-106b-5p to promote the expression of ATPase family AAA domain containing 2 in papillary THCA (11). The lncRNA CNALPTC1 acts as a competing endogenous RNA (ceRNA) by sponging the miR-30 family in THCA (12). Several studies have demonstrated that lncRNA expression is associated with the prognosis of patients with THCA (13-15). Li et al (16) identified 111 lncRNAs that were
differentially expressed between tumor and normal samples in THCA. Furthermore, the lncRNA growth arrest specific 5 was significantly associated with Tumor-Node-Metastasis (TNM) staging, lymph node metastasis, disease-free survival (DFS) and overall survival in THCA (17).

Small nucleolar RNA host gene 7 (SNHG7) is a novel lncRNA involved in the progression of different types of human cancer. lncRNA SNHG7 was first reported to be an oncogenic gene in lung cancer, increasing the expression of Fas apoptotic inhibitory molecule 2 (18). Wang et al (19) demonstrated that lncRNA SNHG7 promotes the proliferation and inhibits apoptosis of gastric cancer cells by repressing P15 and P16 expression. However, the clinical value and functional role of SNHG7 in THCA has not been fully elucidated. The present study investigated the expression pattern and molecular functions of SNHG7 in THCA.

Materials and methods

Analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. The public TCGA (cancergenome.nih.gov) database was used to analyze the expression levels of SNHG7 in THCA. The clinical information of the THCA TCGA dataset was generated from cBioPortal (www.cbioportal.org) (20,21). The 2009 TNM classification of the American Joint Committee on Cancer/International Union Against Cancer was used to stage all the patients (22). The survival analysis, comparing patients with THCA with a high expression level of SNHG7 (SNHG7-high) and those with a low expression level of SNHG7 (SNHG7-low), was performed. In the present study, the web application Cutoff Finder 2012 (molpath.charite.de/cutoff) was used to identify the cut-off value (median expression value) to divide the THCA samples into SNHG7-high and SNHG7-low groups. In order to validate TCGA analysis, two GEO datasets, GSE50901, samples obtained from adjacent healthy tissues from patients with THCA (23), and GSE33630, obtained from healthy controls (24,25), were analyzed. The normalized data were downloaded from the GEO repository (https://www.ncbi.nlm.nih.gov/gds). The normal samples in the TCGA and GSE50901 datasets were adjacent normal tissue samples taken from patients with thyroid cancer. The normal samples in GSE33630 were taken from control patients.

Construction of SNHG7-mediated ceRNA networks. In the present study, SNHG7- targeting microRNAs and mRNAs were predicted using Starbase version 3.0 (http://starbase.sysu.edu.cn/index.php). Subsequently, co-expression analysis was performed for SNHG7 in the TCGA THCA dataset using the cBioPortal online software. The SNHG7-target pairs with co-expression coefficient >0.3 were selected for the construction of SNHG7-associated ceRNA networks. The Cytoscape software version 3.4.0 (www.cytoscape.org) was used for visualization of the co-expression networks.

Co-expression network construction and analysis. According to the expression value of the Pearson's correlation coefficient of SNHG7-gene pairs, SNHG7 co-expressed genes were identified in the present study. The co-expressed SNHG7-gene pairs with an absolute value of Pearson's correlation coefficient ≥0.3 were selected, which included the top 1,000 genes that were co-expressed with SNHG7 in thyroid cancer samples, and the co-expression network was established by using the Cytoscape software.

Protein-protein interaction (PPI) network construction and analysis. By using the Search Tool for the Retrieval of Interacting Genes/Proteins database version 11.0 (STRING #11.0) (26), a PPI network mediated by SNHG7 was constructed using its co-expressing mRNAs (combined score, >0.4). Subsequently, a module analysis of the network was performed using the Mcode plugin (27). The PPI network with the cut-offs of degree ≥2 and of nodes ≥2-core were selected as hub networks.

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. In the present study, GO and KEGG pathway analyses were performed by using the Molecule Annotation System version 3.0 (bioinfo.capitalbio.com/mas3). P<0.05 was considered to indicate a statistically significant difference.

Cell culture and cell transfection. The thyroid gland undifferentiated (anaplastic) carcinoma CAL62 and the thyroid gland squamous SW579 carcinoma cell lines were purchased from the American Type Culture Collection. The cells were incubated in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (ExCell Bio) in an incubator containing 5% CO₂ at 37°C. The small interfering (siRNA) for SNHG7 (5'-UUAGCAGAG UAUUUUGCACUU-3') and siRNA for the negative control (siNC; 5'-UAGCGACUAAACACUAACA-3') were purchased from Guangzhou RiboBio Co., Ltd. The cells were seeded at a density of 3x10⁵ cells/well in 6 -well plates. Following 12 h of incubation in an incubator containing 5% CO₂ at 37°C, the cells were transfected with 50 nM siNC or siSNHG7 using FuGENE® 6 transfection reagent (Promega Corporation). The transfected cells were then used to perform the cell proliferation assay and cell cycle assay.

Cell proliferation assay. Cell proliferation of the transfected cells was detected using the Cell Counting Kit-8 (CCK-8) assay. In brief, the cells were seeded at a density of 1,000 cells/well in the medium in a 96-well plate and cell proliferation was measured at 0, 24, 48 and 72 h. The cells were incubated in an incubator containing 5% CO₂ at 37°C, the cells were transfected with 50 nM siNC or siSNHG7 using FuGENE® 6 transfection reagent (Promega Corporation). The transfected cells were then used to perform the cell proliferation assay and cell cycle assay.

Cell cycle assay. Transfected cells were collected 48 h after transfection, and then the cells were fixed with pre-cooled 70% ethanol, and incubated overnight at 4°C. Subsequently, the cells were washed once with 1 ml PBS, followed by incubation in the dark with 500 µl PBS containing 50 µg/ml propidium iodide, 0.2% Triton X-100 and 100 µg/ml RNase A for 30 min at 4°C. The cell cycle was analyzed using a flow cytometer and the Modfit LT version 4.1 software (Verity Software House, Inc.).
Reverse transcription-quantitative (RT-q)PCR assay. Total RNA was extracted using the E.Z.N.A. Total RNA kit (Omega Bio-Tek, Inc.) 48 h following transfection of the SW579 and CAL62 cell lines. RT was performed using the PrimeScrip RT reagent Kit (Takara Biotechnology Co., Ltd.) according to the manufacturer's instructions. Temperature conditions for the RT reaction were: 37˚C for 15 min; and for reverse transcriptase inactivation reaction, 85˚C for 5 sec. RT-qPCR was performed using the Hieff qPCR SYBR-Green Master mix (YeaSen) according to the manufacturer's instructions. Temperature protocol for pre-denaturation was: 95˚C for 5 min; for PCR reaction (35 cycles), 95˚C for 5 sec and 60˚C for 30 sec. β-actin was used as the internal control. The relative expression was calculated by the $2^{-\Delta\Delta Cq}$ method (28) and every experiment was performed in triplicates. The primer sequences were as follows: SNHG7 forward, 5'-CGA TAC CAT TGA ACA CGC TGC-3' and reverse, 5'-GGT TGA GGG TCC CAG TG-3'; β-actin forward, 5' -CTC CAT CCT GGC CTC GCT GT-3' and reverse, 5'-GCT GTC ACC TTC ACC GTT CC-3'.

Statistical analysis. Statistical analyses and graphical representations were performed using SPSS version 17.0 (SPSS, Inc.) and GraphPad Prism version 6.0 (GraphPad Software, Inc.) Statistical comparisons between two groups were performed using the t-test or the Mann-Whitney U test. Statistical comparisons between two paired groups were performed by the paired t-test. For analysis of >2 groups, one-way analysis of variance followed by Newman-Keuls post hoc test was used. Survival curves were plotted using the Kaplan-Meier method and the differences were examined using the log-rank test. Experiments were repeated at least three times. P<0.05 was considered to indicate a significantly significant difference.

Results

Intronic Non-coding RNA (IncRNA) SNHG7 is upregulated in THCA. In the present study, SNHG7 expression levels in samples from patients with THCA were compared with those in normal samples by analyzing the THCA TCGA dataset. A total of 56 normal samples and 578 tumor samples were included in the TCGA dataset. As presented in Fig. 1A and B, SNHG7 was observed to be markedly upregulated in tumor samples compared with normal samples (P<0.001). In order to validate TCGA analysis, two GEO datasets, GSE50901 (samples obtained...
from adjacent healthy tissues from patients with THCA) (23), and GSE33630 (obtained from healthy controls) (24,25), were analyzed. SNHG7 expression levels were increased in THCA samples compared with normal samples (P<0.001 and P<0.05; Fig. 1C and D).

High expression of SNHG7 is associated with progression of thyroid cancer. Subsequently, the association between SNHG7 expression levels and clinicopathological features, including age, sex, grade, T and N stage and the recurrence status, were evaluated. The analysis revealed that SNHG7 was downregulated in female patients with THCA compared with male patients with THCA (P<0.05; Fig. 2A). Furthermore, SNHG7 expression was increased in patients with stage III and stage IV compared with patients with stage I (P<0.05) and stage II (P<0.01) THCA (P<0.05; Fig. 2B).

SNHG7 expression was revealed to be significantly upregulated in stage T3 and T4 patients compared with stage T1 and T2 patients (P<0.05; Fig. 2C). This analysis demonstrated that an increased lncRNA SNHG7 expression level was associated with advanced pathology stages in THCA.

lncRNA SNHG7 is associated with poor prognosis in THCA. To further investigate the clinical significance of lncRNA SNHG7 in THCA, SNHG7 expression and survival time in patients with THCA was subsequently analyzed. The results obtained demonstrated that a higher expression level of SNHG7 was closely associated with shorter DFS time in thyroid cancer (P<0.001; median DFS time, 56.11 vs. 67.22 months, respectively). *P<0.05, as indicated. SNHG7, small nucleolar RNA host gene 7; T, tumor; DFS, disease-free survival.

Construction of SNHG7 mediated PPI networks in THCA. By using the ‘guilt-by-association’ approach, the potential roles of SNHG7 should be similar with its downstream targets. Thus, we predicted potential roles of SNHG7 using SNHG7-regulating mRNAs. Co-expression analysis for SNHG7 in THCA was subsequently performed. The absolute values of Pearson's correlation coefficient ≥0.3 were selected as the cut-off to identify reliable SNHG7-mRNA pairs.

In addition, SNHG7 mediated PPI networks in thyroid cancer were also constructed. The top two positively co-expressed hub modules are presented in Fig. 3, and the top two negatively co-expressed hub modules are presented in Fig. 4. Positive-related module 1 contained 97 nodes and 4,438 edges, whereas positive-related module 2 contained 51 nodes and 697 edges. Furthermore, negative-related module 1 contained 24 nodes and 276 edges, and negative-related module 2 contained 35 nodes and 182 edges.

GO and KEGG pathway analysis of SNHG7 mediated hub PPI networks in THCA. GO and KEGG pathway analysis of SNHG7 mediated hub PPI networks in thyroid cancer were
subsequently performed using Cytoscape’s ClueGo plug-in. Significant biological processes and pathways (P<0.05) are presented in the present study. The results revealed that SNHG7 positive-related module 1 was involved in regulating cytoplasmic translation, translation elongation, signal-recognition particle-dependent co-translational protein targeting to membrane and ribosome assembly, whereas SNHG7 positive-related module 2 was associated with positive regulation of the viral life cycle, RNA processing and mRNA splicing.

Furthermore, SNHG7 negative-related module 1 was revealed to be involved in regulating histone ubiquitination and ubiquitin-mediated proteolysis, and SNHG7 negative-related module 1 was revealed to be involved in endoplasmic reticulum (ER)-to-Golgi vesicle-mediated transport, sister chromatid cohesion and DNA damage checkpoint regulation.

**Knockdown of SNHG7 inhibits THCA cell proliferation and cell cycle in vitro.** In order to further validate the roles of SNHG7 in thyroid cancer, a loss-of-function assay was performed in the CAL62 and SW579 cell lines. As shown in Fig. 5A and C, transfection with siSNHG7 significantly decreased the mRNA expression of SNHG7 in CAL62 and SW579 cells compared with the negative control (P<0.05). The CCK-8 assay was performed to evaluate the effect of SNHG7 knockdown on cell proliferation. As presented in Fig. 5, knockdown of SNHG7 significantly inhibited proliferation in CAL62 (P<0.05; Fig. 5B) and SW579 (P<0.01; Fig. 5D) cells after 4 days.

As abnormal cell cycle progression is a hallmark of cancer (29,30), the role of SNHG7 knockdown in regulating the cell cycle was investigated by flow cytometry in CAL62 and
SW579 cells (Fig. 5E-H). SNHG7 knockdown increased the percentage of cells in the G1 phase and decreased the percentage of cells in the S phase compared with control cells. Furthermore, SNHG7 knockdown decreased the percentage of cells in G2 phase in the CAL62 cells compared with control cells, but no significant difference was observed in the SW579 cells (P<0.01).

Discussion

An increasing number of studies have demonstrated the IncRNAs serve important roles in various types of human cancer, including prostate (31,32), breast (33,34), lung (35,36) and THCA (37). Specific IncRNAs have been reported to be involved in THCA progression. For example, Pvt1 oncogene was the first IncRNA revealed to be associated with the regulation of THCA cell proliferation by increasing the expression of thyroid-stimulating hormone receptor (38). Xu et al (39) observed that the IncRNAs ENST00000537266 and ENST00000426615 served roles in papillary THCA growth and metastasis. H19 imprinted maternally expressed transcript was found to be a ceRNA by ‘sponging’ miR-17-5p to regulate the expression of YES proto-oncogene 1 Src family tyrosine kinase in THCA (40). The present study revealed, to the best of the authors' knowledge for the first time, that IncRNA SNHG7 is upregulated in, and associated with the prognosis of, THCA.
SNHG7 is a novel IncRNA that has been reported to have an oncogenic role in different types of human cancer. SNHG7 is upregulated in esophageal (41) and prostate cancer (42), glioblastoma (43), non-small cell lung (44) and gastric cancer (19). However, the roles of SNHG7 in THCA have yet to be elucidated. In the present study, analysis of the TCGA dataset revealed that SNHG7 was upregulated in THCA tissues compared with normal samples. Notably, high expression of SNHG7 was associated with the progression of THCA. SNHG7 was upregulated in advanced-stage (stages III and IV) compared with the low-stage (stages I and II) THCA samples. Furthermore, the present study revealed, to the best of the authors’ knowledge for the first time, that higher expression levels of SNHG7 were closely associated with shorter overall survival and DFS times in THCA. Taken together, the results obtained in the current study suggest that SNHG7 is an oncogene in THCA.

In conclusion, the present study has demonstrated that SNHG7 was markedly upregulated in THCA samples compared with control samples through an analysis of TCGA datasets. SNHG7 expression levels were increased in advanced-stage compared with early-stage THCA samples. Additionally, a higher expression level of SNHG7 was associated with shorter survival times compared with a lower expression level. The results obtained in the current study suggest that SNHG7 may be used to predict the prognosis of patients with THCA. The present study suggested that SNHG7 may serve as a new therapeutic and prognostic target for THCA.
Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
LC and LJZ designed the study. LC, LJZ and JZ developed the methodology. LC, LJZ and JZ analyzed and interpreted the data, and wrote and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Chen YJ, Jemal A and Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115: 3801-3807, 2009.
2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212, 2013.
3. Huang P, Mao LF, Zhang ZP, Lv WW, Feng XP, Liao HJ, Dong C, Kim KE, Seong YJ, et al: Aberrant activation of notch signaling in papillary thyroid cancer cells. Cancer Res 76: 582-593, 2016.
4. Yang L, Xie X, Zeng M, Liu X, et al: The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, maintains H3K27me3 methylation. Genome Biol 16: 52, 2015.
5. Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in thyroid cancer. J Clin Endocrinol Metab 100: E890-E899, 2015.
6. Barros-Filho MC, Marchi FA, Pinto CA, Rogatto SR and Sirokman K, Surka C, Kadri S, Xing J, Goren A, Lander ES, et al: Integrative analysis of microRNA and mRNA expression to spread across the X chromosome. Science 341: 1237973, 2013.
32. Wan X, Huang W, Yang S, Zhang Y, Pu H, Fu F, Huang Y, Wu H, Li T and Li Y: Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget 7: 60503-60518, 2016.

33. Kumar M, DeVaux RS and Herschkowitz JI: Molecular and cellular changes in breast cancer and new roles of lncRNAs in breast cancer initiation and progression. Prog Mol Biol Transl Sci 144: 563-586, 2016.

34. Li T, Liu Y, Xiao H and Xu G: Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer 24: 535-543, 2017.

35. Park SM, Choi EY, Bae DH, Sohn HA, Kim SY and Kim YJ: The LncRNA EPEL promotes lung cancer cell proliferation through E2F target activation. Cell Physiol Biochem 45: 1270-1283, 2018.

36. Tao H, Yang JJ, Zhou X, Deng ZY, Shi KH and Li J: Emerging role of long noncoding RNAs in lung cancer: Current status and future prospects. Respir Med 110: 12-19, 2016.

37. Kim D, Lee WK, Jeong S, Seol MY, Kim H, Kim KS, Lee EJ, Lee J and Jo YS: Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer. Mol Cell Endocrinol 431: 36-45, 2016.

38. Zhou Q, Chen J, Feng J and Wang J: Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol 37: 3105-3113, 2016.

39. Xu B, Shao Q, Xie K, Zhang Y, Dong T, Xia Y and Tang W: The long non-coding RNA ENST00000537266 and ENST00000426615 influence papillary thyroid cancer cell proliferation and motility. Cell Physiol Biochem 38: 368-378, 2016.

40. Liu L, Yang J, Zhu X, Li D, Lv Z and Zhang X: Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J 283: 2236-2239, 2016.

41. Xu LJ, Yu XJ, Wei B, Hui HX, Sun Y, Dai J and Chen XF: LncRNA SNHG7 promotes the proliferation of esophageal cancer cells and inhibits its apoptosis. Eur Rev Med Pharmacol Sci 22: 2653-2661, 2018.

42. Qi H, Wen B, Wu Q, Cheng W, Lou J, Wei J, Huang J, Yao X and Weng G: Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503. Biomed Pharmacother 102: 326-332, 2018.

43. Ren J, Yang Y, Xue J, Xi Z, Hu L, Pan SJ and Sun Q: Long noncoding RNA SNHG7 promotes the growth and progression of glioblastoma via inhibition of miR-5095. Biochem Biophys Res Commun 496: 712-718, 2018.

44. She K, Yan H, Huang J, Zhou H and He J: miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer. Cell Prolif: Nov 12, 2017 (Epub ahead of print). doi: 10.1111/cpr.12406.

45. Chen W, Zhang X, Li J, Huang S, Xiang S, Hu X and Liu C: Comprehensive analysis of coding-lncRNA gene co-expression network uncovers conserved functional IncRNAs in zebrafish. Bmc Genomics 19 (Suppl 2): S112, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.